KL003 Cell Injection Drug Product
Small molecule
KL003 Cell Injection Drug Product is one of 38 small molecule programs targeting Thalassemia. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
84 competitors in Thalassemia
#DrugCompanyPhaseTrials
1Legalon
BBukwang Pharmaceutical
Phase 3
Winrevair
Merck & Co.Phase 2
Neoral
NovartisPhase 2
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2
Jakafi
IncytePhase 2
Dacogen
Sun PharmaPhase 2
Droxia
TTheravia
Phase 2
Endari
EEmmaus Medical, Inc.
Phase 2
CTX001
Vertex PharmaceuticalsPhase 3
Campath
GGenzyme, a Sanofi Company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]